Long-term follow-up of people with type 1 diabetes after earlier immune-treatment trials
Follows people with type 1 diabetes to track insulin production and immune changes.
Plain-language title generated from the registry record
Registry title: Type 1 Diabetes Extension Study
Key facts
- Where
- Atlanta, Aurora, Boston, Indianapolis, Iowa City, Kansas City, Minneapolis, New Haven, San Francisco, Seattle, Sioux Falls, and Stanford, United StatesSee the 12 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 35 years old?
Source: NCT02734277, who can take part
Where in United States
- Emory UniversityAtlanta, United StatesNo longer taking part
- University of Colorado School of Medicine: Barbara Davis Center for DiabetesAurora, United StatesTaking people
- Joslin Diabetes CenterBoston, United StatesTaking people
- Indiana University/Riley Hospital for ChildrenIndianapolis, United StatesTaking people
- University of Iowa Health Care Division of Pediatric EndocrinologyIowa City, United StatesTaking people
- Children's Mercy HospitalKansas City, United StatesNo longer taking part
- University of MinnesotaMinneapolis, United StatesTaking people
- Yale UniversityNew Haven, United StatesNo longer taking part
- UCSF School of MedicineSan Francisco, United StatesTaking people
- Benaroya Research InstituteSeattle, United StatesTaking people
- Sanford ResearchSioux Falls, United StatesNo longer taking part
- Stanford UniversityStanford, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Trial code
- NCT02734277
- Record updated
- 18 September 2026
- Original description
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).Read full original descriptionShow less
Type 1 Diabetes Extension Study
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
* follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin.
This information could help design better therapies for type 1 diabetes in the future.
Inclusion: Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study; Ability to sign informed consent/assent (as applicable for children).
Exclusion: Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or; Inability to comply with the study visit schedule and required assessments.